Valeant Pharmaceuticals entered into a licensing agreement with Norgine for a bowel-cleansing oral solution used to prepare for colonoscopies.
EndoChoice reported total revenue for the second quarter of 2016 was $19.3 million, but net loss for the second quarter totaled $24.7 million.
EndoChoice’s Lumos received FDA clearance and was recently launched in the United States.
More articles on GI/endoscopy:
5 most read GI/endoscopy stories: Aug. 1 — Aug. 5
EndoChoice launches the Lumos imaging software system: 4 takeaways
Dr. Farzana Rashid Hossain appointed to 1st Philadelphia Commission for Women — 4 thoughts
